Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.
We report a patient with the McCune-Albright syndrome and growth hormone excess. Biochemical evaluation demonstrated characteristic changes typical of acromegaly, and an unusual pattern of delayed somatotropin response to hGHRH40, not previously described in this syndrome. Therapeutic trial of low-dose octreotide successfully reversed his growth hormone excess, whereas bromocriptine failed to reduce growth hormone levels. Previous reports of acromegaly and McCune-Albright syndrome are reviewed, and the unique features of this case discussed.
Sherman
S I
SI
Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Ladenson
P W
PW
D001971:Bromocriptine / Q000627:therapeutic use; D005359:Fibrous Dysplasia, Polyostotic / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010901:Pituitary Function Tests
D001971:Bromocriptine; D013006:Growth Hormone; D015282:Octreotide